Tevogen Inc.
No SEC Form 4 filings for $TVGN in the last 30 days.
See all $TVGN insider activity →Tevogen Inc. (TVGN) reports Ryan H. Saadi now owns 74.4% of its shares, including 9.77M restricted shares. The company granted Saadi 8M additional restricted shares, vesting only if TVGN achieves $1B in revenue by 2031.
Tevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Restricted Stock Awards On September 14, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted the Company’s execut
Tevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 24, 2026, Tevogen Inc. (the “Company”) held an annual meeting of its stockholders (the “Annual Meeting”). As note
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TVGN (Tevogen Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent TVGN coverage spans corporate actions, financial news and market movers.
The large performance‑based grant aligns insider incentives with future revenue growth, potentially supporting upside if the target is met.
Equity grants increase insider ownership but are contingent on future performance, likely limiting immediate price impact.
The share authorization increase may dilute existing shareholders but provides flexibility for future equity compensation; the charter change streamlines future shareholder actions.
The move is speculative, but the acquisition evaluation and potential revenue uplift provide a narrative catalyst.
Initiative creation plus potential MSO/CRO acquisitions signals a shift toward recurring, services-led revenue, contingent on deal consummation.
AlphAI scores every news story that mentions TVGN with an AI model for sentiment and relevance, and aggregates insider trades from Tevogen Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tevogen Inc. (TVGN) reports Ryan H. Saadi now owns 74.4% of its shares, including 9.77M restricted shares. The company granted Saadi 8M additional restricted shares, vesting only if TVGN achieves $1B in revenue by 2031.
1 min readTevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Restricted Stock Awards On September 14, 2026 (the “Grant Date”), Tevogen Inc. (the “Company”) granted the Company’s execut
1 min readTevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 24, 2026, Tevogen Inc. (the “Company”) held an annual meeting of its stockholders (the “Annual Meeting”). As note
1 min readBiotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
6 min readTevogen Bio Holdings (Nasdaq: TVGN) said it formed a healthcare services initiative to broaden its revenue-generating business. William Keane, VP Strategic Initiatives, will lead it interim while the company evaluates acquiring an MSO and CRO. Tevogen estimates the potential combined annual revenue at about $100 million, subject to deal completion.
3 min readSciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.
6 min readTevogen (Nasdaq: TVGN) said it is making progress on strategic acquisition initiatives that, if completed, could generate about $100 million in combined annual revenue. The company is evaluating a contract research organization (CRO) and other healthcare-platform acquisitions. Any deals depend on due diligence, definitive agreements, approvals, and closing conditions, and may not be consummated.
4 min readTevogen Bio Holdings (Nasdaq: TVGN) said it is continuing evaluations for strategic acquisitions, including a previously announced review of a contract research organization (CRO) and other opportunities for its healthcare platform. If consummated, the deals could support about $100 million in combined annual revenue, subject to due diligence, approvals, and closing conditions.
2 min readTevogen Bio (TVGN) filed an amended annual report (10-K/A) for 2025 to include Part III information, which typically covers governance, executive compensation, and related-party transactions, without updating financial results. The amendment details the company's board structure, executive pay—including CEO Ryan Saadi's $10.4 million total compensation in 2025—and significant related-party financial arrangements with The Patel Family, LLP and its affiliates. It also specifies that CEO Ryan Saadi beneficially owns 59.45% of outstanding common stock, with all directors and executives collectively holding 67.91%.
3 min readTevogen Bio Holdings shareholders approved an amendment to the company's 2024 equity incentive plan and authorized a flexible reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board's discretion. Both proposals received strong support, aimed at adjusting the capital structure and equity incentives. TipRanks' AI Analyst, Spark, rates TVGN as Neutral due to very weak financial performance and a strong downtrend in technicals.
3 min read
